Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Metro, R. Chiari (2016)
Preface on "Emerging treatment options for brain metastases from non-small cell lung cancer".Translational lung cancer research, 5 6
B. Creelan, T. Yeh, Sang-We Kim, N. Nogami, Dong-Wan Kim, L. Chow, S. Kanda, Rosemary Taylor, Weifeng Tang, M. Tang, H. Angell, M. Roudier, M. Marotti, D. Gibbons (2020)
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancerBritish Journal of Cancer, 124
G. Metro, A. Gili, D. Signorelli, A. Toma, M. Garaffa, D. Galetta, P. Economopoulou, A. Friedlaender, B. Jiménez, A. Collazo-Lorduy, A. Addeo, P. Chiarini, C. Costa, G. Mountzios, F. Roila (2021)
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysisClinical and Translational Oncology, 23
A. Addeo, A. Friedlaender, G. Banna, G. Weiss (2021)
TMB or not TMB as a biomarker: That is the question.Critical reviews in oncology/hematology
J. González-Navajas, Dengxia Fan, Shuang Yang, Fengyuan Yang, B. Lozano-Ruiz, L. Shen, Jongdae Lee (2021)
The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor TherapiesFrontiers in Immunology, 12
J. Mazières, A. Drilon, A. Lusque, L. Mhanna, A. Cortot, L. Mezquita, A. Thai, C. Mascaux, S. Couraud, R. Veillon, M. Heuvel, J. Neal, N. Peled, M. Früh, T. Ng, V. Gounant, S. Popat, J. Diebold, J. Sabari, V. Zhu, S. Rothschild, P. Bironzo, A. Martínez-Martí, A. Curioni-Fontecedro, R. Rosell, Mickaël Lattuca-Truc, M. Wiesweg, B. Besse, B. Solomon, F. Barlesi, R. Schouten, H. Wakelee, D. Camidge, G. Zalcman, S. Novello, S. Ou, J. Milia, O. Gautschi (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryAnnals of Oncology, 30
Royster Hedgepeth (2016)
An Exploratory Analysis
M. Gubens, L. Sequist, J. Stevenson, S. Powell, L. Villaruz, S. Gadgeel, C. Langer, A. Patnaik, H. Borghaei, S. Jalal, J. Fiore, J. Ge, H. Raftopoulos, L. Gandhi (2016)
Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.Journal of Clinical Oncology, 34
A. Lisberg, A. Cummings, J. Goldman, K. Bornazyan, N. Reese, T. Wang, P. Coluzzi, B. Ledezma, M. Mendenhall, Jaime Hunt, Brian Wolf, Benjamin Jones, John Madrigal, John Horton, M. Spiegel, J. Carroll, Jaklin Gukasyan, T. Williams, Lauren Sauer, C. Wells, Ariana Hardy, P. Linares, C. Lim, L. Ma, Carlos Adame, E. Garon (2017)
A Phase II Study of Pembrolizumab in EGFR‐Mutant, PD‐L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLCJournal of Thoracic Oncology, 13
G. Metro, G. Banna, D. Signorelli, A. Gili, D. Galetta, G. Galli, P. Economopoulou, F. Roila, A. Friedlaender, A. Camerini, A. Christopoulou, O. Cantale, A. Toma, P. Pizzutilo, B. Jiménez, A. Collazo-Lorduy, A. Calles, P. Baxevanos, H. Linardou, P. Kosmidis, D. Giannarelli, G. Mountzios, A. Addeo (2020)
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%Journal of Immunotherapy, 43
K. Isomoto, K. Haratani, H. Hayashi, S. Shimizu, S. Tomida, T. Niwa, T. Yokoyama, Y. Fukuda, Y. Chiba, R. Kato, J. Tanizaki, Kaoru Tanaka, M. Takeda, T. Ogura, T. Ishida, Akihiko Ito, K. Nakagawa (2020)
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung CancerClinical Cancer Research, 26
M. Hellmann, N. Rizvi, J. Goldman, S. Gettinger, H. Borghaei, J. Brahmer, N. Ready, D. Gerber, L. Chow, R. Juergens, F. Shepherd, S. Laurie, W. Geese, S. Agrawal, Tina Young, Xuemei Li, S. Antonia (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.The Lancet. Oncology, 18 1
Shun-li Peng, Rong Wang, Xiaojuan Zhang, Yueyun Ma, Longhui Zhong, Ke Li, A. Nishiyama, S. Arai, S. Yano, Wei Wang (2019)
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expressionMolecular Cancer, 18
G. Oxnard, J.C. Yang, H. Yu, Sang Kim, H. Saka, L. Horn, K. Goto, Y. Ohe, H. Mann, K. Thress, M. Frigault, K. Vishwanathan, D. Ghiorghiu, S. Ramalingam, M. Ahn (2020)
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology
(2015)
Prior TKI therapy in NSCLC EGFR mutant patients associates with lack of response to anti-PD-1 treatment
The importance of detecting targetable EGFR mutations in NSCLC: know your exon
C. Lee, J. Man, S. Lord, M. Links, V. Gebski, T. Mok, J. Yang (2017)
Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐AnalysisJournal of Thoracic Oncology, 12
Y. Simoni, E. Becht, M. Fehlings, C. Loh, S. Koo, K. Teng, J. Yeong, R. Nahar, Tong Zhang, H. Kared, Kaibo Duan, N. Ang, M. Poidinger, Yin Lee, A. Larbi, A. Khng, E. Tan, Cherylin Fu, Ronnie Mathew, M. Teo, W. Lim, C. Toh, B. Ong, T. Koh, A. Hillmer, A. Takano, T. Lim, E. Tan, Weiwei Zhai, D. Tan, I. Tan, E. Newell (2018)
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltratesNature, 557
Z. Chalmers, Caitlin Connelly, D. Fabrizio, L. Gay, Siraj Ali, Riley Ennis, A. Schrock, B. Campbell, A. Shlien, J. Chmielecki, F. Huang, Yuting He, James Sun, U. Tabori, Mark Kennedy, Daniel Lieber, S. Roels, Jared White, G. Otto, J. Ross, L. Garraway, V. Miller, P. Stephens, G. Frampton (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 9
Seung Lee, Yu Kim, M. Sung, Mi-Sook Lee, Joungho Han, H. Kim, Yoon-La Choi (2019)
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR MutationInternational Journal of Molecular Sciences, 20
M. Garassino, B. Cho, Joo‐Hang Kim, J. Mazières, J. Vansteenkiste, H. Léna, J. Jaime, J. Gray, J. Powderly, C. Chouaid, P. Bidoli, P. Wheatley-Price, Keunchil Park, R. Soo, Yi-fan Huang, C. Wadsworth, P. Dennis, N. Rizvi (2018)
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.The Lancet. Oncology, 19 4
J. Yang, S. Gadgeel, L. Sequist, Chien-Liang Wu, V. Papadimitrakopoulou, W. Su, J. Fiore, S. Saraf, H. Raftopoulos, A. Patnaik (2019)
Pembrolizumab in Combination With Erlotinib or Gefitinib as First‐Line Therapy for Advanced NSCLC With Sensitizing EGFR MutationJournal of Thoracic Oncology, 14
Kenneth To, W. Fong, W. Cho (2021)
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New StrategiesFrontiers in Oncology, 11
J. Galon, Daniela Bruni (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapiesNature Reviews Drug Discovery, 18
L. Park, Kyunghoon Rhee, W. Kim, A. Cho, Junho Song, J. Anker, Michael Oh, P. Bais, Sandeep Namburi, Jeffrey Chuang, Y. Chae (2018)
Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC).Journal of Clinical Oncology, 36
K. Hastings, H.A. Yu, W. Wei, F. Sánchez-Vega, M. Deveaux, J. Choi, H. Rizvi, A. Lisberg, A. Truini, C. Lydon, Z. Liu, B. Henick, A. Wurtz, G. Cai, A. Plodkowski, N. Long, D. Halpenny, J. Killam, I. Oliva, N. Schultz, Gregory Riely, M. Arcila, M. Ladanyi, D. Zelterman, R. Herbst, S. Goldberg, M. Awad, E. Garon, S. Gettinger, M. Hellmann, K. Politi (2019)
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancerAnnals of Oncology, 30
Maria Toki, N. Mani, James Smithy, Yuting Liu, M. Altan, Brad Wasserman, Rasikh Tuktamyshov, K. Schalper, K. Syrigos, D. Rimm (2018)
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC MutationsJournal of Thoracic Oncology, 13
X. Le, M. Negrão, A. Reuben, L. Federico, L. Diao, D. McGrail, M. Nilsson, J. Robichaux, I. Munoz, Sonia Patel, Y. Elamin, Youhong Fan, Won-Chul Lee, E. Parra, L. Soto, Runzhe Chen, Jun Li, T. Karpinets, R. Khairullah, H. Kadara, C. Behrens, B. Sepesi, Ruiping Wang, Mingrui Zhu, Linghua Wang, Ara Vaporiciyan, J. Roth, S. Swisher, C. Haymaker, Jianhua Zhang, Jing Wang, Kwok-kin Wong, L. Byers, C. Bernatchez, Jianjun Zhang, I. Wistuba, D. Gibbons, E. Akbay, J. Heymach (2020)
Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
M. Gubens, L. Sequist, J. Stevenson, S. Powell, L. Villaruz, S. Gadgeel, C. Langer, A. Patnaik, H. Borghaei, S. Jalal, J. Fiore, S. Saraf, H. Raftopoulos, L. Gandhi (2019)
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.Lung cancer, 130
DP Carbone, M Reck, L Paz-Ares (2017)
First-line nivolumab in stage IV or recurrent non-small-cell lung cancerN Engl J Med, 376
Xinan Wang, B. Ricciuti, Tom Nguyen, Xihao Li, M. Rabin, M. Awad, Xihong Lin, B. Johnson, D. Christiani (2021)
Association between Smoking History and Tumor Mutation Burden in Advanced Non–Small Cell Lung CancerCancer Research, 81
M. Qiao, Tao Jiang, S. Ren, C. Zhou (2021)
MA13.06 Deciphering the Characterization of Tumor Microenvironment in EGFR-Mutated Non-Small Cell Lung CancerJournal of Thoracic Oncology, 16
Jia Luo, C. Bandlamudi, B. Ricciuti, N. Vokes, A. Schoenfeld, J. Egger, J. Sauter, A. Plodkowski, I. Preeshagul, M. Kris, E. Allen, B. Taylor, H. Rizvi, M. Donoghue, M. Awad, M. Hellmann (2020)
Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).Journal of Clinical Oncology, 38
D. Carbone (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung CancerOncology Times
S. Gettinger, N. Rizvi, L. Chow, H. Borghaei, J. Brahmer, N. Ready, D. Gerber, F. Shepherd, S. Antonia, J. Goldman, R. Juergens, S. Laurie, F. Nathan, Yun Shen, C. Harbison, M. Hellmann (2016)
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 25
A. Schoenfeld, H. Rizvi, C. Bandlamudi, J. Sauter, W. Travis, N. Rekhtman, A. Plodkowski, R. Perez-Johnston, P. Sawan, A. Beras, J. Egger, M. Ladanyi, K. Arbour, C. Rudin, Gregory Riely, B. Taylor, M. Donoghue, M. Hellmann (2020)
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.Annals of oncology : official journal of the European Society for Medical Oncology
C. Lee, J. Man, S. Lord, W. Cooper, M. Links, V. Gebski, R. Herbst, R. Gralla, T. Mok, J. Yang (2017)
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysisJAMA Oncology, 4
S. Peters, S. Gettinger, M. Johnson, P. Jänne, M. Garassino, D. Christoph, C. Toh, N. Rizvi, J. Chaft, E. Costa, J. Patel, L. Chow, M. Koczywas, Cheryl Ho, M. Früh, M. Heuvel, J. Rothenstein, M. Reck, L. Paz-Ares, F. Shepherd, T. Kurata, Zhengrong Li, J. Qiu, M. Kowanetz, S. Mocci, G. Shankar, A. Sandler, E. Felip (2017)
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 24
Z. Dong, Jia-Tao Zhang, S. Liu, J. Su, Chao Zhang, Z. Xie, Qing Zhou, H. Tu, Chongrui Xu, Li-xu Yan, Yu‐Fa Li, W. Zhong, Yi-long Wu (2017)
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancerOncoImmunology, 6
Treatment with immune checkpoint inhibitors (ICIs) that target the programmed cell death 1/programmed cell death ligand-1 (PD-1/PD-L1) axis is usually ineffective in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), either as first-line treatment or in later lines. By contrast, especially for patients with common EGFR mutations (exon 19 deletion/L858R point mutation), an orally bioavailable EGFR tyrosine kinase inhibitor (EGFR-TKI) is the best upfront therapy, being able to provide response rates well above 50% and a median progression-free survival ranging from 11 to 19 months, depending on whether a second-generation (e.g., afatinib) or a third-generation (i.e., osimertinib) EGFR-TKI is used. Unfortunately, treatment options for these patients at the time of acquired resistance are limited. As for afatinib-pretreated patients, those who develop a T790M mutation may benefit from osimertinib, whereas platinum-based chemotherapy is the preferable therapeutic strategy for T790M-negative patients as well as for patients who progress on osimertinib administered as first-line therapy. Here, we describe the case of an exon-19-deleted patient who experienced a complete response to the anti-PD-1 agent pembrolizumab upon the development of T790M-negative acquired resistance to afatinib. Furthermore, we discuss this case in the context of the existing literature, especially focusing on the importance of evaluating multiple markers of immune response post-EGFR-TKI and prior to ICI treatment in order to select the best treatment strategy in this clinical scenario.
Oncology and Therapy – Springer Journals
Published: Jun 1, 2022
Keywords: Afatinib; EGFR mutation; EGFR-TKI, immune checkpoint inhibitors; PD-L1; Tumor mutation burden
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.